Genetically modified tumour vaccines carrying inserted genes for immunoregulatory molecules

Folia Biologica

Volumn 42, Issue 6, 1996, Pages 295-304

  Bubenik J ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

CD80; Gene therapy; IL 2

Indexed keywords

INTERLEUKIN 2; TUMOR ANTIGEN; TUMOR VACCINE; CANCER VACCINE; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR; RECOMBINANT VACCINE;

CANCER IMMUNIZATION; CELL INTERACTION; CONFERENCE PAPER; EFFECTOR CELL; GENE INSERTION; IMMUNOGENETICS; IMMUNOREGULATION; SIGNAL TRANSDUCTION; SPLEEN CELL; ANIMAL; BIOSYNTHESIS; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASM; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOKINES; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; INTERLEUKIN-2; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 0030323022     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Article

References (114)

1. Accolla, R. S., Adorini, L., Sartoris, S., Sinigaglia, F., Guardiola, J. (1995) MHC: orchestrating the immune response. Immunol. Today 16, 8-11.
2. Allione, A., Consalvo, M., Nanni, P., Lollini, P. L., Cavallo, F., Giovarelli, M., Forni, M., Gulino, A., Colombo, M. P., Dellabona, P., Hock, H., Blankenstein, T., Rosenthal, F. M., Gansbacher, B., Bosco, M. C., Musso, T., Gusella, L., Forni, G. (1994) Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage-colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res. 54, 6022-6026.
3. Allison, J. P., Hurwitz, A. A., Leach, D. R. (1995) Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr. Opin. Immunol. 7, 682-686.
4. Anichini, A., Mortarini, R., Alberti, S., Mantovani, A., Parmiani, G. (1993) T-cell-receptor engagement and tumor ICAM-1 upregulation are required to bypass low susceptibility of melanoma cells to autologous CTL-mediated lysis. Int. J. Cancer 53, 994-1001.
5. Baskar, S., Ostrand-Rosenberg, S., Nabavi, N., Nadler, L. M., Freeman, G. J., Glimcher.L. H. (1993) Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 90, 5687-5690.
6. Becker, Y. (1992) Anticancer role of dendritic cells (DC) in human and experimental cancers. A review. Anticancer Res. 12, 511-520.
7. Becker, Y. (1993) Dendritic cell activity against primary tumors: An overview. In vivo 7, 187-192.
8. Bernards, R., Dessain, S. K., Weinberg, R. A. (1986) N-myc amplification causes down-modulation of MHC class I expression in neuroblastoma. Cell 47, 667-670.
9. Bonssiotis, V. A., Gribben, J. G., Freeman, G. J., Nadler, L. M. (1994) Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. Curr. Open. Immunol. 6, 794-807.
10. Boon, T. (1992) Toward a genetic analysis of tumor rejection antigens. Adv. Cancer Res. 58, 177-210.
11. Bubeník, J. (1989) Local immunotherapy of cancer with interleukin 2. Immunol. Lett. 21, 267-274.
12. Bubeník, J. (1990a) Tumor inhibitory effects of regional interleukin 2 administration and the role of lymphokine-activated killer cells. In: Role of Interleukin-2 Activated Killer Cells in Cancer, eds. Lotzová, E., Herberman, R., pp. 235-244, CRC Press, Boca Raton, FL.
13. Bubeník, J. (1990b) Guest Editorial: Local and regional immunotherapy of cancer with interleukin 2. J. Cancer Res. Clin. Oncol. 116, 1-7.
14. Bubeník, J. (1993a) IL-2 and gene therapy of cancer. Int. J. Oncol. 2, 1049-1052.
15. Bubeník, J. (1993b) Editorial: IL-2 gene therapy of cancer - at its beginning. Folia Biol (Praha) 39, 279-288.
16. Bubeník, J. (1994) Utilization of IL-2 and IL-2 gene transfer forregional immunotherapy of cancer. In: Cytokine-Induced Tumor Immunogenicity. From Exogenous Molecules to Gene Therapy, eds. Forni, G., Foa, R., Santoni, A., Fratti, L., pp. 113-130, Academic Press, London.
17. Bubeník, J. (1996) Cytokine gene-modified vaccines in the therapy of cancer. Pharmacol. Ther. 69, 1-14.
18. Bubeník, J., Indrová, M., Perlmann, P., Berzins, K., Mach, O., Kraml, J., Toulcová, A. (1985) Tumour inhibitory effects of TCGF (IL-2)-containingpreparations. Cancer Immunol. Immunother. 19, 57-61.
19. Bubeník, J., Kieler, J., Tromholt, V., Hermann, G., Jandlová, T. (1988a) Defect in lectin-induced interleukin 2 production by peripheral blood lymphocytes of patients with invasive urinary bladder carcinoma. Immunol. Lett. 18, 115-118.
20. Bubeník, J., Voitenok, N. N., Kieler, J., Prassolov, V. S., Chumakov, P. M., Bubeníková, D., Šímová, J., Jandlová, T. (1988b) Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol. Lett. 19, 279-282.
21. Bubeník, J., Šímová, J., Jandlová, T. (1990) Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol. Lett. 23, 287-292.
22. Bubeník, J. Lotzová, E., Indrová, M., Šímová, J., Jandlová, T., Bubeníková, D. (1992a) Use of IL-2 gene transfer in local immunotherapy of cancer. Cancer Lett. 62, 257-262.
23. Bubeník, J., Šímová, J., Bubeníková, D. (1992b) Interleukin 2 and cancer. Folia Biol. (Praha) 38, 155-169.
24. Bubeník, J., Zeuthen, J., Indrová, M., Bubeníková, D., Šímová, J. (1994) Kinetics and function of peritoneal exudate cells during local IL-2 gene therapy of cancer. Int. J. Oncol. 4, 13-16.
25. Bubeník, J., Šímová, J., Bubeníková, D., Zeuthen, J., Indrová, M. (1995a) Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment J. Cancer Res. Clin. Oncol. 121, 39-43.
26. Bubeník, J., Bubeníková, D., Šímová, J., Lotzová, E. (1995b) Interleukin 2 (IL-2) and gene therapy of cancer: treatment of myeloid leukaemia with irradiated, genetically modified IL-2-producing cell vaccine. J. Exp. Clin. Cancer Res. (Suppl.) 14, 83-86.
27. Chen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P., Linsley, P. S. (1992) Costimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102.
28. Chen, L., Linsley, P. S., Hellström, K. E. (1993) Costimulation of T cells for tumor immunity. Immunol. Today 14, 483-495.
29. Chen, L., McGowan, P., Ashe, S., Johnston, J. , Li, Y., Hellström, I., Hellström, K. E., (1994a) Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179, 523-532.
30. Chen, L., McGowan, P., Ashe, S., Johnston, J. V., Hellström, I., Hellström. K. E. (1994b) B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res. 54, 5420-5423.
31. Connor, J., Bannerji, R, Saito, S. Heston, W., Fair, W., Gilboa, E (1993) Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J. Exp. Med. 177, 1127-1134.
32. Damle, N. K., Klussman, K., Leytze, G., Ochs, H. D., Aruffo, A., Linsley, P. S., Ledbetter, J. A. (1993) Costimulation via vascular cell adhesion molecule-I induces in T cells increased responsiveness to the CD28 counter-receptor. Cell. Immunol. 148, 144-156.
33. Doyle, A., Martin, W. J., Funa, K., Gazdar, A., Carney, D., Martin, S. E., Linnoila, I., Cuttia, F., Mulshine, J., Bunn, P., Minna, J. (1985) Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small cell lung cancer. J. Exp. Med. 161, 1135-1139.
34. Dunussi-Joannopoulos, K., Weinstein, H. J., Nickerson, P. W., Strom, T. B., Burakoff, S. J., Croop, J. M., Arceci, R. J. (1996) Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 87, 2938-2946.
35. Elliott, B. E., Carlow, D. A., Rodricks, A.-M., Wade, A. (1989) Perspectives on the role of MHC antigens in normal and malignant cell development. Adv. Cancer Res. 53, 181-244.
36. Elliott, L. H., Roszman, T. L., Brooks, W. H. (1984) Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. J. Immunol. 132, 1208-1215.
37. Elliott, L., Brooks, W., Roszman, T. (1987) Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas. J. Natl. Cancer Inst. 78, 919-922.
38. Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. J., Simons, J. W., Karasuyama, H., Vogelstein, B., Frost, P. (1990) Interleukin 2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403.
39. 1-Interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res. 53, 1107-1112.
40. Flyer, D. C., Burakoff, S. J., Faller, D. V. (1985) Retrovirus-induced changes in major histocompatibility complex antigen expression influence susceptibility to lysis by cytotoxic T lymphocytes. J Immunol. 135, 2287-2292.
41. Foa, R., Guarini, A., Cignetti, A., Cronin, K. Rosenthal, F., Gansbacher, B. (1994) Cytokine gene therapy: a new strategy for the management of cancer patients. Nat. Immun. 13, 67-75.
42. Freeman, G. J., Freedman, A. S., Segil, J. M., Lee, G., Whitman, J. F., Nadler, L. M. (1989) B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol. 143, 2714-2722.
43. Freeman, G. J., Borriello, F., Hodes, R. J., Reiser, H., Gribben, J. G., Ng, J. W., Kim, J., Goldberg, J. M., Hathcock, K., Laszlo, G., Lombard, L. A., Wang, S., Gray, G. S., Nadler, L. M., Sharpe, A. H. (1993) Murine B7-2, an alternative CTLA-4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J. Exp. Med. 178, 2185-2190.
44. Gansbacher, B., Bannerji, R., Daniels, B., Zier, K., Cronin, K., Gilboa, E. (1990a) Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long-lasting antitumor immunity. Cancer Res. 50, 7820-7825.
45. Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., Gilboa, E. (1990b) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224.
46. Germain, R. N. (1994) MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76, 287-299.
47. Gimmi, C., Freeman, G., Gribben, J., Gray, G., Nadler, L. (1993) Human T-cell anergy is induced by antigen presentation in the absence of B7 co-stimulation. Proc. Natl. Acad. Sci. USA 90, 6586-6590.
48. Grabbe, S., Beissert, S., Schwarz, T., Granstein, R. D. (1995) Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol. Today 16, 117-121.
49. Guinan, E. C., Gribben, J. G., Boussiotis, V. A., Freeman, G. J., Nadler, L. M. (1994) Pivotal role of the B7: CD28 pathway in transplantation tolerance and tumor immunity. Blood 84, 3261-3282.
50. 1 mice. Int. J. Oncol. 7, 233-238.
51. Hellström, K. E., Hellström, I., Chen, L. (1995) Can co-stimulated tumor immunity be therapeutically efficacious? Immunol. Rev. 145, 123-145.
52. Herberman, R. B., Gorelik, E. (1989) Role of the natural immune system in control of primary tumors and metastasis. In: Functions of the Natural Immune System, eds. Reynolds, C. W., Wiltrout, R. H., pp. 3-37, Plenum Publishing Corporation, New York.
53. Holden, C. A., Sanderson, A. R., McDonald, D. M. (1983) Absence of human leukocyte antigens in skin tumors and some cutaneous appendages: evidence using monoclonal antibodies. J. Am. Acad. Dermatol. 9, 867-871.
54. Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., Levitsky, H. (1994) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigenes. Science 264, 961-965.
55. Hui, K., Grosveld, F., Festenstein, H. (1985) Rejection of transplantable AKR leukemia cells following MHC DNA-mediated cell transformation. Nature 311, 750-753.
56. Hui, K. M., Sim, T. F., Foo, T. T., Oei, A.-A. (1989) Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene. J. Immunol. 143, 3835-3843.
57. Ichikawa, M., Tsudo, M. (1991) Impaired expression of interleukin 2 receptors in childhood acute lymphoblastic leukemia. Leukaemia Res. 15, 591-595.
58. Ikemoto, S., Wada, S., Kamizuru, M., Hayahara, N., Kishimoto, T., Maekawa, M. (1992) Clinical studies on cell mediated immunity in patients with renal cell carcinoma: interleukin-2 and interferon-γ production of lymphocytes. Cancer Immunol. Immunother. 34, 289-293.
59. Janeway Jr., C. A., Bottomby, K. (1994) Signals and signs for lymphocyte responses. Cell 76, 275-285.
60. Jenkins, M. K. (1994) The ups and downs of T cell costimulation. Immunity 1, 443-446.
61. Jenski, L. J., Ledford, T. (1985) Murine leukemic cells inhibit IL-2 production by susceptible syngeneic splenocytes. J. Immunol. 135, 3178-3183.
62. Jones, E. A., Bodmer, W. F. (1980) Lack of expression of HLA antigens on choriocarcinoma cell lines. Tissue Antigens 16, 195-199.
63. June, C. H., Ledbetter, J. A., Linsley, P. S., Thompson, C. B. (1990) Role of the CD28 receptor in T-cell activation. Immunol. Today 11, 211-216.
64. Kedar, E., Klein, E. (1992) Cancer immunotherapy: are the results discouraging? Can they be improved? Adv. Cancer Res. 59, 245-322.
65. Lampson, L. A., Fisher, C. A., Whelan, J. P. (1983) Striking paucity of HLA-A. -B. -C and β2-microglobulin on human neuroblastoma cell lines. J. Immunol. 130. 2471-2474.
66. Leach, D. R., Callahan, G. N. (1995) Fibrosarcoma cells expressing allogeneic MHC class II antigens induce protective antitumor immunity. J. Immunol. 154, 738-743.
67. Ley, V., Langlade-Demoyen, P., Kourilsky, P., Larsson-Sciard, E. L. (1991) Interleukin 2 dependent activation of tumor-specific cytotoxic T lymphocytes invivo. Eur. J. Immunol. 21, 851-854.
68. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153, 421-428.
69. Linsley, P. S., Brady, W., Grosmaire, L., Aruffo, A., Damle, N. K., Ledbetter, J. A. (1991a) Binding of the B cell activation antigen B7 to CD 28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173, 721-730.
70. Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., Ledbetter, J. A. (1991b) CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174, 561-569.
71. Masuno, T., Ikeda, T., Yokota, S., Komuta, K., Ogura, T., Kishimoto, S. (1986) Immunoregulatory T-lymphocyte functions in patients with small cell lung cancer. Cancer Res. 46, 4195-4199.
72. Momburg, F., Koch, S. (1989) Selective loss of β2-microglobulin mRNA in human colon carcinoma. J. Exp. Med. 169, 309-314.
73. Momburg, F., Ziegler, A. Harpprecht, J. (1989) Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma. J. Immunol. 142, 352-358.
74. Nabel, E. G., Yang, Z., Muller, D., Chang, A. E., Gao, X., Huang, G. L., Cho, K. J., Nabel, G. J. (1994) Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanoma. Hum. Gene Ther. 5, 1089-1095.
75. Nabel, G. J., Nabel, E. G., Yang, Z., Fox, B. A., Plautz, G. E., Gao, X., Huang, L., Shu, S., Gordon, D., Chang, A. E. (1993) Direct gene transfer with DNA liposome complexes in melanoma: expression, biological activity and lack of toxicity in humans. Proc. Natl. Acad. Sci. USA 90, 11307-11311.
76. Nakamura, Y., Wakimoto, H., Abe, J., Kanegae, Y., Saito, I., Aoyagi, M., Hirakawa, K., Hamada, H. (1994) Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2. Cancer Res. 54, 5757-5760.
77. Neefjes, J. J., Momburg, F., Hämmerling, G. J. (1993) Selective and ATP-dependent translocation of peptides by MHC-encoded transporter. Science 261, 769-771.
78. Norton, S. D., Zuckerman, L., Urdahl, K. B., Shefner, R., Miller, J., Jenkins, M. K. (1992) The CD28 ligand B7 enhances IL-2 production by providing a costimulatory signal to T cells. J. Immunol. 149, 1556-1559.
79. Ostrand-Rosenberg, S. (1994) Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr. Opin. Immunol. 6, 722-727.
80. Porgador, A., Gansbacher, B., Bannerji, R., Tzehoval, E., Gilboa, E., Feldman, M., Eisenbach, L. (1993) Anti- metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int. J. Cancer 53, 471-477.
81. Razi-Wolf, Z., Freeman, G. J., Calvin, F., Benacerraf, B., Nadler, L., Reiser, H. (1992) Expression and function of the murine B7 antigen, the major costimulatory molecules expressed by peritoneal exudate cells. Proc. Natl. Acad. Sci. USA 89, 4210-4214.
82. Reiter, Z. (1993) Dual effects of cytokines in regulation of MHC-unrestricted cell mediated cytotoxicity. Crit. Rev. Immunol. 13, 1-34.
83. Restifo, N. P., Kawakami, Y., Marincola, F., Skamamian, P., Taggarse, A., Esquivel, F., Rosenberg, S. A. (1993) Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. J. Immunother. 14, 182-190.
84. Rey, A., Klein, B., Zagury, D., Thierry, C., Serou, B. (1983) Diminished interleukin-2 activity production in cancer patients bearing solid tumors and its relationship with natural killer cells. Immunol. Lett. 6, 175-178.
85. Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., Goldberg, A. L. (1994) Inhibitors of proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78, 761-771.
86. Saito, S., Bannerji, R., Gansbacher, B., Rosenthal, F. M., Romanenko, P., Heston, W. D. W, Fair, W. R., Gilboa, E. (1994) Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res. 54, 3516-3520.
87. Schrier, P. I., Bernards, R., Vaessen, T. M. J., Honwellig, A., van der Erb, A. J. (1983) Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature 305, 771-773.
88. Schumacher, T. N. M., Kantesaria, D. V., Heemels, M. T., Ashton-Rickardt, P. G., Shepherd, J. C., Früh, K., Young, Y., Peterson, P. A., Tonegawa, S., Ploegh, H. L. (1994) Peptide length and sequence specificity of mouse TAP1/TAP2 translocator. J. Exp. Med. 179, 533-540.
89. Seliger, B., Höhne, A., Knuth, A., Bernhard, H., Meyer, T., Tampe, R., Momburg, F., Huber, C. (1996) Analysis of the major histocompatibilily complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res. 56, 1756-1760.
90. Sobol, R. E., Fakhrai, H., Shawler, D., Gjerset, R., Dorigo, O., Carson, C., Khaleghi, T., Koziol, J., Shiftan, T. A., Royston, I. (1995) Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. 2, 164-167.
91. Soulillou, J. P., Douillard, J. J., Vie, H., Harousseau, J. L., Guenel, J., Le Mevel-Le Pourhiet, A., Le Mevel, B. (1985) Defect in lectin-induced interleukin 2 (IL-2) production by peripheral blood lymphocytes of patients with Hodgkin's disease. Eur. J. Cancer Clin. Oncol. 21, 935-939.
92. Spies, T., Bresnahan, M., Bahraru, S., Arnold, D., Blanck, G., Mellins, E., Pious, D., De Mars, R. T. (1990) A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 348, 744-747.
93. Strayer, D. S., Horowitz, M., Leibowitz, J. L. (1986) Immunosuppression in viral oncogenesis. III. Effects of virus infection on interleukin 1 and interleukin 2 generation and responsiveness. J. Immunol. 137, 3632-3638.
94. Symington, F. W., Santos, E. B. (1991) Lysis of human keratinocytes by allogeneic HLA class I-specific cytotoxic T cells. J. Immunol. 146, 2169-2175.
95. Šímová, J., Bubeník, J., Hausner, P., Klener, P., Cinader, B. (1987) Expression of IL-2 receptors on peripheral blood lymphocytes from young adult and aged human donors. Folia Biol. (Praha) 33, 282-286.
96. Tanaka, K., Isselbacher, K. J., Khoury, G., Jay, G. (1985) Reversal of oncogenesis by the expression of a major histocompatibility class I gene. Science 228, 26-28.
97. Teramura, Y., Watanabe, Y., Kan, N., Matsuda, T., Kuribayashi, K. (1993) Interferon-γ-producing tumor induces host tumor- specific T cell responses. Jpn. J. Cancer Res. 84, 689-696.
98. Townsend, A., Bodmer, H. (1989) Antigen recognition by class I-restricted T lymphocytes. Annu. Rev. Immunol., 7, 601-624.
99. + T cells by B7-transfected melanoma cells. Science 259, 368-370.
100. Townsend, S. E., Su, F. W., Atherton, J. M., Allison, J. P. (1994) Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54, 6477-6483.
101. Tsai, S.- C. J., Gansbacher, B., Tait, L., Miller, F. R., Heppner, G. H. (1993) Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J. Natl. Cancer Inst. 85, 546-553.
102. Turcovski-Corrales, S. M., Fenton, R. G., Peltz, G., Taub, D. D. (1995) CD 28:B7 interactions promote T cell adhesion. Eur. J. Immunol. 25, 3087-3093.
103. Uckert, W., Walther, W. (1994) Retrovirus-mediated gene transfer in cancer therapy. Pharmacol. Ther. 63, 323-347.
104. Vaillier, D., Daculsi, R., Legrand, E., Guillemain, B. (1990) Natural killer activity, production of interteron-gamma and interleukin 2 in immunodeficient C57BL/6 mice injected with RadLV-Rs viral complex. Immunobiology 180, 195-207.
105. Vieweg, J., Rosenthal, F. M., Bannerji, R., Heston, W. D. W., Fair, W. R., Gansbacher, B., Gilboa, E. (1994) Immunotherapy of prostate cancer in the Durnning rat model: use of cytokine gene modified tumor vaccines. Cancer Res. 54, 1760-1765.
106. Wallich, R., Bulbuc, N., Hammerling, G. J., Katsav, S., Segal, S., Feldman, M. (1985) Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315, 301-303.
107. Watanabe, Y., Kuribayashi, K., Miyatake, S., Nishihara, K., Nakayama, E.-I., Taniyama, T., Sakat, T.-A. (1989) Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl. Acad. Sci. USA 86, 9456-9460.
108. Webb, S., Morris, C., Sprent, J. (1990) Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 63, 1249-1256.
109. Weber, J. S., Jay, G., Tanaka, K., Rosenberg, S. A. (1987) Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection. J. Exp. Med. 166, 1716-1733.
110. Yang, G., Hellström, K. E., Hellström, I., Chen, L. (1995) Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154, 2794-2800.
111. Yeh, K.-Y., Pulaski, B. A., Woods, M. L., McAdam, A. J., Gaspari, A. A., Frehinger, J. G., Lord, E. M. (1995) B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma. Cell. Immunol. 165, 217-224.
112. Yewdell, J. W., Bennink, J. R. (1992) Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv. Immunol. 52, 1-123.
113. Yoshida, S., Takai, N., Tanaka, R. (1987) Functional analysis of interleukin-2 in immune surveillance against brain tumors. Neurosurgery 21, 627-630.
114. Zamkoff, K. W., Reeves, W. G., Paolozzi, F. P., Poiesz, B. J., Comis, R. L., Tomar, R. H. (1985) Impaired interleukin regulation of the phytohemagglutinin response in Hodgkin's disease. Clin. Immunol. Immunopathol. 35, 111-124.